Business UpdateJun 15, 2026, 09:27 AM
Elicio Therapeutics Refines Phase 3 Strategy After Pancreatic Cancer Study Results
AI Summary
Elicio Therapeutics announced results from its Phase 2 AMPLIFY-7P study for ELI-002 7P in adjuvant pancreatic cancer. While the study did not meet its primary disease-free survival endpoint in the overall population, post-hoc analyses revealed a stronger treatment effect in R0 resected patients and a correlation between T cell responses and improved DFS. The company is refining its Phase 3 strategy to focus on R0 patients with extended dosing and is exploring financing and partnership opportunities. Elicio anticipates its current cash will fund operations through Q4 2026.
Key Highlights
- Phase 2 AMPLIFY-7P study did not meet its primary DFS endpoint in the intent-to-treat population.
- Post-hoc analysis showed a stronger DFS hazard ratio in the R0 (completely resected) population (HR 0.65, p=0.048).
- Mutant KRAS-specific T cell responses strongly correlated with improved DFS (HR 0.22, p<0.0001).
- Refined Phase 3 development strategy will focus on R0 resected patients and additional ELI-002 7P dosing.
- Company expects current cash to support operations into the fourth quarter of 2026.
- Elicio is evaluating strategic financing and partnering opportunities.
Price Impact
More from ELTX